1. >
  2. News & Events
  3. >
  4. Press Releases

Press Releases

Found 289 Results
Page 2 of 29

Onxeo’s Combined General Meeting on June 10, 2021 in camera: availability of preparatory documents and live webcast login information


Paris (France), May 21, 2021 – 5:45 p.m. CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo”, […]

05/21/2021


Publication of the 2020 Annual Financial Report


Paris (France), April 23, 2021 – 7.00 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: […]

Tags:

04/23/2021


Onxeo Reports Full-Year 2020 Financial Results and Provides Business Update


Several major clinical milestones achieved in 2020 by AsiDNA™, including promising initial results in combination with chemotherapy and the launch […]

04/21/2021


Onxeo announces the success of its Rights Issue with €9.7 million raised


This transaction will accelerate the development of the Company and its portfolio and extend its financial horizon to the end […]

04/12/2021


Onxeo to Present New Preclinical Data at AACR 2021


Confirming the effect of AsiDNA™ on resistance to KRAS inhibitors Introducing OX400, a new generation of PARP interfering cancer drug […]

Tags: ,

04/08/2021


B-Smart – Interview of Judith Greciet, CEO of Onxeo


Watch the interview (in French)

03/26/2021


Onxeo will publish its annual results on April 21, 2021


The Annual General Meeting will be held on June 10, 2021 Paris (France), March 24, 2021 – 6 pm CET […]

Tags:

03/24/2021


Onxeo Launches a Rights Issue to accelerate its R&D programs


This transaction will secure the financing of the strategy and the resources necessary to achieve key clinical milestones until at […]

03/10/2021



Onxeo publishes Letter to Shareholders and provides update on its developments


Paris (France), February 2, 2021 – 9 pm CET – Onxeo S.A. (Euronext Growth: ALONX; Nasdaq First North: ONXEO), a […]

02/02/2021


Page 2 of 29